Sight Sciences revenue jumps 25% as guidance raised
Alpha Vantage · scanx.trade · · AI-summarised by FinFlash
Sight Sciences posted record third-quarter revenue of $24.9 million, up 25% year-over-year, driven by both its Interventional Glaucoma and Interventional Dry Eye segments. The company raised full-year 2026 revenue guidance to $92-93 million and significantly cut cash burn, moving toward cash flow breakeven. Analysts hold five Buy ratings with a Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context